Passage Bio reports positive Phase 1/2 trial results for PBFT02 in frontotemporal dementia, with planned protocol amendments for safety optimization. Passage Bio, Inc. announced positive results from ...
Krystal Biotech, Inc. announced the dosing of the first patient in its Phase 1/2 clinical trial, EMERALD-1, which is evaluating KB801, an eye drop gene therapy for neurotrophic keratitis (NK), a rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback